CHANDAN vs SUDEEPPHRM: Stock Comparison
SUDEEP PHARMA is the larger company by market capitalisation. CHANDAN shows a lower P/E, while SUDEEP PHARMA shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CHANDAN leads 2; SUDEEPPHRM leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | CHANDAN | SUDEEPPHRM |
|---|---|---|
| Live Price | — | ₹1,155 |
| Day Change | — | 4.49% |
| Volume | — | 2.17 L |
| 52-Week High | — | ₹1,378 |
| 52-Week Low | — | ₹524.05 |
| Distance from 52W High | — | -16.18% |
Valuation
| Metric | CHANDAN | SUDEEPPHRM |
|---|---|---|
| Market Cap | ₹495 Cr | ₹13,102 Cr |
| P/E Ratio | 22.4x | 71.65x |
| P/B Ratio | 3.55x | 14.83x |
| EPS | ₹2.74 | ₹3.59 |
| Book Value | ₹72.1 | ₹79.51 |
| Dividend Yield | 0% | 0.13% |
Growth
| Metric | CHANDAN | SUDEEPPHRM |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -39.81% | 49.76% |
| Qtr Profit Growth | -10.49% | 19.98% |
Profitability & Leverage
| Metric | CHANDAN | SUDEEPPHRM |
|---|---|---|
| ROE | 16.2% | 21.62% |
| ROCE | 14.55% | 19.78% |
| Net Margin | 0% | 27.14% |
| Operating Margin | 15.97% | 35.72% |
| Debt to Equity | 0.3x | 0.17x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | CHANDAN | SUDEEPPHRM |
|---|---|---|
| Promoter Holding | 49.61%▲ 0.06 pp | 76.15% |
| FII Holding | 0.01% | 1.81%▲ 0.26 pp |
| DII Holding | 5.09%▲ 0.06 pp | 15.65%▼ 2.46 pp |
| Public Holding | 45.29%▼ 0.13 pp | 6.39%▲ 2.21 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CHANDAN and SUDEEP PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.